Tempest Therapeutics
TPST
50 hedge funds and large institutions have $21.9M invested in Tempest Therapeutics in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 10 closing their positions.
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
6% more funds holding
Funds holding: 47 → 50 (+3)
21% less capital invested
Capital invested by funds: $27.9M → $21.9M (-$5.97M)
62% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.1M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$734K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$575K |
| 4 |
LCM
Laurion Capital Management
New York
|
+$474K |
| 5 |
Two Sigma Investments
New York
|
+$348K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.99M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$1.59M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
-$1.14M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$562K |
| 5 |
D.E. Shaw & Co
New York
|
-$365K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
52
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
BWM
53
Baystate Wealth Management
Boston,
Massachusetts
| $1K | – | – | – |
|
|
PAM
54
Panagora Asset Management
Boston,
Massachusetts
| $1K | – | – | – |
|
|
RE
55
RBC Europe
London,
United Kingdom
| $140 | – | – | – |
|
|
EC
56
EcoR1 Capital
San Francisco,
California
| – | -$4.99M | -1,201 | Closed |
|
|
ACA
57
Avoro Capital Advisors
New York
| – | -$1.59M | -384 | Closed |
|
|
GC
58
GMT Capital
Atlanta,
Georgia
| – | -$1.14M | -274 | Closed |
|
|
NCMW
59
Northern Capital Management (Wisconsin)
Madison,
Wisconsin
| – | -$129K | -31 | Closed |
|
|
VF
60
Virtu Financial
New York
| – | -$92K | -22 | Closed |
|
61
Citadel Advisors
Miami,
Florida
| – | -$83K | -20 | Closed |
|
62
Janus Henderson Group
London,
United Kingdom
| – | -$45K | -11 | Closed |
|
|
ECM
63
Element Capital Management
New York
| – | -$21K | -5 | Closed |
|
64
Dimensional Fund Advisors
Austin,
Texas
| – | -$16K | -4 | Closed |
|
|
TRCT
65
Tower Research Capital (TRC)
New York
| – | -$4K | -1 | Closed |
|
TPST Hedge Fund Activity: Q4 2017 in Review
50 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2017, worth a combined $21.9M — down 21% from $27.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TPST positions and 10 closed out — a net gain of 3 holders — while 5 added to existing stakes and 13 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.1M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.99M sold.
- 50 institutional investors held Tempest Therapeutics (TPST) as of Q4 2017, up from 47 in Q3 2017.
- Funds reported $21.9M of Tempest Therapeutics stock for Q4 2017, down 21% quarter-over-quarter.
- 13 funds opened new Tempest Therapeutics positions in Q4 2017 and 10 closed out, a net change of +3 holders.
- The largest Tempest Therapeutics buyer in Q4 2017 was Renaissance Technologies, an estimated $1.1M added.
- The largest Tempest Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $4.99M sold.
Based on aggregated 13F filings for Q4 2017.